Please login to the form below

Not currently logged in
Email:
Password:

Merck's first-in-class Zontivity cleared in US

FDA approves the protease-activated receptor-1 antagonist to reduce heart attack risk

Merck & CoAfter a long haul, Merck & Co's Zontivity has become the first drug in the new protease-activated receptor-1 (PAR-1) antagonist class to be approved for marketing in the US.

The anti-platelet drug has been cleared by the FDA to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart attack or blockages in the arteries to the legs.

Trials of the drug in patients suffering a heart attack or with peripheral arterial disease showed that vorapaxar was able to reduce the risk of heart attack, stroke and death from 9.5 per cent to 7.9 per cent over three years, according to the FDA.

Approval of vorapaxar was expected after an FDA advisory committee backed it earlier this year, although the prospects for the drug looked dim a couple of years ago when two studies raised questions about its safety, specifically an increased risk of intracranial haemorrhage (ICH) in patients with a history of stroke.

The FDA said vorapaxar will carry a boxed warning to alert prescribers about the risk of ICH, and stressed that the drug should not be used in patients who have a history of stroke or transient ischaemic attacks (TIA) or mini strokes.

Originally developed by Schering-Plough - which Merck acquired in 2009 - vorapaxar had been tipped as a potential $5bn-a-year product before the safety issues emerged.

Now, its sales prospects are considerably more modest with some analysts predicting sales well below $500m a year given the risk:benefit ratio and competition in the marketplace from other antiplatelet drugs such as AstraZeneca's Brilinta/Brilique (ticagrelor) and Daiichi Sankyo/Eli Lilly's Effient (prasugrel) as well as generic clopidogrel.

Merck plans to launch Zontivity in the US in the coming weeks, while the PAR-1 antagonist is also under regulatory review in Europe for the same indication.

Article by
Phil Taylor

12th May 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics